Latest Investments News

IVE Group Limited reported a robust FY25 with significant profit growth and margin expansion, driven by strategic logistics expansions and the rising Lasoo e-commerce platform. Despite a softer FY26 start, the company maintains steady dividends and growth ambitions.

Centuria Capital Group has expanded its agriculture portfolio by acquiring Australia’s largest hydroponic glasshouse facility in South Australia for $168 million, boosting its agriculture assets under management by 25%.

Atturra Limited reported a robust 24% increase in both revenue and underlying EBITDA for FY25, propelled by its cloud platform, AI innovations, and defence sector contracts. The company forecasts continued momentum into FY26 with ambitious growth targets.

Pantoro Gold reports exceptional high-grade underground drilling results at its Norseman Gold Project, advancing plans to commence mining within the next year.

Iress Ltd has responded to recent media speculation about a potential acquisition, clarifying it cannot confirm any deal terms while continuing discussions with multiple parties.

IPD Group’s 2025 AGM reveals robust FY25 financial results driven by data centre and electrification sectors, alongside operational efficiencies and sustainability strides. The company signals continued momentum into FY26 with positive earnings guidance.

Whitefield Income Ltd reports robust first-quarter earnings and announces a $53 million capital raising via placement and a Share Purchase Plan, maintaining its focus on delivering steady, franked dividends.

Australian Foundation Investment Company plans special fully franked dividends alongside its 2026 interim and final payouts, leveraging a strong franking credit balance.

L1 Long Short Fund Limited has updated its dividend notification to include the Dividend Reinvestment Plan price, confirming a fully franked quarterly payout and new issue securities.

Acrux Ltd reported a remarkable surge in licensing revenue from its topical generics portfolio alongside a strategic pivot towards innovative drug delivery R&D at its 2025 Annual General Meeting.

Aroa Biosurgery reported a 14% rise in product sales to NZ$44.6 million for the half-year ended September 2025, driven by strong growth in its Myriad portfolio. The company also posted a normalised EBITDA profit and reaffirmed its FY26 revenue and profit guidance.

Whitefield Income Limited has launched a A$53 million placement at a 5.2% discount to recent prices, aiming to bolster its investment strategy with fresh capital.